ViewRay: peers
ViewRay beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
ViewRay, Guided Therapeutics Inc., ENvue Medical, Inc., Escalon Medical Corp., Nu-Med Plus Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | ViewRaybase VRAY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nuwellis, Inc. NUWE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Guided Therapeutics Inc. GTHP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nexalin Technology, Inc. NXL · 🇺🇸 US Percentile in Healthcare Percentile in USA | ENvue Medical, Inc. FEED · 🇺🇸 US Percentile in Healthcare Percentile in USA | Escalon Medical Corp. ESMC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nu-Med Plus Inc. NUMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | NeuroOne Medical Technologies Corporation NMTC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $4 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8 | $3 MOct 30, 2026 · Market data4th of 8 | $7 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8 | $2 MOct 27, 2026 · Market data5th of 8 | $2 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $2 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8 | $2 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one6th of 8 | $8 MOct 30, 2026 · Market data1st of 8 | $3 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $8 MFY2025 · SEC3rd of 6 | $1 MFY2025 · SEC5th of 6 | $0 MFY2025 · SEC6th of 6 | $3 MFY2025 · SEC4th of 6 | $13 MFY2026 · SEC1st of 6 | —— | $9 MFY2025 · SEC2nd of 6 | $5 M6 ranked |
| Net income (Higher is better) | —— | $-18 MFY2025 · SEC6th of 7 | $-3 MFY2025 · SEC3rd of 7 | $-8 MFY2025 · SEC5th of 7 | $-18 MFY2025 · SEC7th of 7 | $4 MFY2026 · SEC1st of 7 | $-0 MFY2025 · SEC2nd of 7 | $-4 MFY2025 · SEC4th of 7 | $-4 M7 ranked |
| Employees (Better neither way: ranked highest first) | 267As on 2021 · Profile1st of 5 | 38December 31, 2025 · Profile3rd of 5 | —— | 8December 31, 2025 · Profile5th of 5 | —— | 40June 30, 2026 · Profile2nd of 5 | —— | 18September 30, 2025 · Profile4th of 5 | 385 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | -5.4%FY2025 · SEC4th of 417th17th | ———— | ———— | -0.4%FY2025 · SEC3rd of 425th28th | +5.7%FY2026 · SEC2nd of 439th48th | ———— | +163.8%FY2025 · SEC1st of 495th98th | +2.7%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | -1.1%FY2025 · SEC4th of 424th29th | ———— | ———— | +50.4%FY2025 · SEC2nd of 488th96th | +1.5%FY2026 · SEC3rd of 431st38th | ———— | +276.9%FY2025 · SEC1st of 4100th100th | +25.9%4 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 61.9%FY2025 · SEC1st of 455th76th | ———— | ———— | 5.9%FY2025 · SEC4th of 44th5th | 43.7%FY2026 · SEC3rd of 428th56th | ———— | 56.5%FY2025 · SEC2nd of 447th70th | 50.1%4 ranked |
| Operating margin (Higher is better) | ———— | -134.3%FY2025 · SEC3rd of 420th9th | ———— | ———— | -897.6%FY2025 · SEC4th of 41st0th | 0.4%FY2026 · SEC1st of 458th41st | ———— | -46.5%FY2025 · SEC2nd of 432nd15th | -90.4%4 ranked |
| Net margin (Higher is better) | ———— | -211.8%FY2025 · SEC3rd of 414th5th | ———— | ———— | -712.9%FY2025 · SEC4th of 43rd1st | 31.5%FY2026 · SEC1st of 495th95th | ———— | -39.7%FY2025 · SEC2nd of 434th16th | -125.8%4 ranked |
| Free cash flow margin (Higher is better) | ———— | -131.8%FY2025 · SEC3rd of 418th7th | ———— | ———— | -369.8%FY2025 · SEC4th of 49th2nd | -3.1%FY2026 · SEC1st of 447th28th | ———— | -32.1%FY2025 · SEC2nd of 432nd15th | -81.9%4 ranked |
| Return on equity (Higher is better) | ———— | -382.9%FY2025 · SEC5th of 53rd1st | ———— | -221.3%FY2025 · SEC4th of 59th4th | -106.5%FY2025 · SEC3rd of 523rd10th | 102.2%FY2026 · SEC1st of 599th99th | ———— | -91.5%FY2025 · SEC2nd of 527th11th | -106.5%5 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | 0.3×price Oct 30, 2026 · Market data3rd of 35th10th | ———— | 7.8×price Oct 27, 2026 · Market data1st of 368th86th | ———— | ———— | ———— | 0.9×price Oct 30, 2026 · Market data2nd of 315th27th | 0.9×3 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 1.2×price Oct 30, 2026 · Market data1st of 322nd26th | ———— | 0.6×price Oct 27, 2026 · Market data3rd of 38th8th | ———— | ———— | ———— | 1.2×price Oct 30, 2026 · Market data1st of 322nd26th | 1.2×3 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -34.6%price Oct 30, 2026 · Market dataonly one with it24th10th | -34.6%— |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | ———— | -3.8×FY2025 · SEC2nd of 359th33rd | ———— | ———— | 5.0×FY2026 · SEC1st of 386th74th | -5.0×FY2025 · SEC3rd of 355th30th | ———— | -3.8×3 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 4 of 18FY2025 · Scorecard5th of 7 | 0 of 8FY2025 · Scorecard7th of 7 | 2 of 12FY2025 · Scorecard6th of 7 | 3 of 13FY2025 · Scorecard4th of 7 | 8 of 15FY2026 · Scorecard1st of 7 | 3 of 9FY2025 · Scorecard3rd of 7 | 8 of 19FY2025 · Scorecard2nd of 7 | 23% passed7 ranked |
| Valuation checks (Higher is better) | —— | 2 of 4FY2025 · Scorecard1st of 3 | —— | 1 of 4FY2025 · Scorecard3rd of 3 | —— | —— | —— | 2 of 5FY2025 · Scorecard2nd of 3 | 40% passed3 ranked |
| Growth checks (Higher is better) | —— | 0 of 6FY2025 · Scorecard5th of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 0 of 1FY2025 · Scorecard5th of 7 | 2 of 6FY2025 · Scorecard4th of 7 | 4 of 6FY2026 · Scorecard2nd of 7 | 1 of 2FY2025 · Scorecard3rd of 7 | 4 of 5FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | —— | 1 of 5FY2025 · Scorecard2nd of 7 | 0 of 2FY2025 · Scorecard4th of 7 | 0 of 3FY2025 · Scorecard4th of 7 | 0 of 5FY2025 · Scorecard4th of 7 | 3 of 5FY2026 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard4th of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard2nd of 7 | 0 of 3FY2025 · Scorecard7th of 7 | 1 of 3FY2025 · Scorecard2nd of 7 | 1 of 2FY2025 · Scorecard1st of 7 | 1 of 3FY2026 · Scorecard2nd of 7 | 1 of 4FY2025 · Scorecard6th of 7 | 1 of 3FY2025 · Scorecard2nd of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard2nd of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | —— | 0 of 1FY2026 · Scorecard2nd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 53.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3 | —— | 0.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3 | —— | —— | —— | 18.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 3 | 18.3%3 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 3 | —— | 92026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3 | —— | —— | —— | 222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3 | 113 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | +23.8 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | +23.8 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = ViewRay: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nuwellis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Guided Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nexalin Technology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ENvue Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Escalon Medical Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nu-Med Plus Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeuroOne Medical Technologies Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| ViewRay | — | — | — |
| Nuwellis, Inc. | -134.3%FY2025 | 20th percentile in Healthcaremedian -7.7%, 674 companies | 9th percentile in USAmedian 3.5%, 2,594 companies |
| Guided Therapeutics Inc. | — | — | — |
| Nexalin Technology, Inc. | — | — | — |
| ENvue Medical, Inc. | -897.6%FY2025 | 1st percentile in Healthcaremedian -7.7%, 674 companies | 0th percentile in USAmedian 3.5%, 2,594 companies |
| Escalon Medical Corp. | 0.4%FY2026 | 58th percentile in Healthcaremedian -7.7%, 674 companies | 41st percentile in USAmedian 3.5%, 2,594 companies |
| Nu-Med Plus Inc. | — | — | — |
| NeuroOne Medical Technologies Corporation | -46.5%FY2025 | 32nd percentile in Healthcaremedian -7.7%, 674 companies | 15th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | ViewRay | Nuwellis, Inc. | Guided Therapeutics Inc. | Nexalin Technology, Inc. | ENvue Medical, Inc. | Escalon Medical Corp. | Nu-Med Plus Inc. | NeuroOne Medical Technologies Corporation |
|---|---|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | $13 MSEC | — | — |
| 2025 | — | $8 MSEC3rd | $1 MSEC5th | $0 MSEC6th | $3 MSEC4th | $12 MSEC1st | — | $9 MSEC2nd |
| 2024 | — | $9 MSEC2nd | $0 MSEC6th | $0 MSEC5th | $3 MSEC4th | $12 MSEC1st | — | $3 MSEC3rd |
| 2023 | — | $9 MSEC2nd | — | $0 MSEC5th | $2 MSEC3rd | $12 MSEC1st | — | $2 MSEC4th |
| 2022 | — | $9 MSEC2nd | — | — | $1 MSEC3rd | $11 MSEC1st | — | $0 MSEC4th |
| 2021 | — | $8 MSEC2nd | $0 MSEC6th | $0 MSEC5th | $2 MSEC3rd | $10 MSEC1st | — | $0 MSEC4th |
| 2020 | — | $7 MSEC2nd | $0 MSEC4th | — | $1 MSEC3rd | $9 MSEC1st | — | — |
| 2019 | — | $6 MSEC2nd | $0 MSEC4th | — | $1 MSEC3rd | $10 MSEC1st | — | — |
| 2018 | — | $5 MSEC2nd | $0 MSEC4th | — | $0 MSEC3rd | $11 MSEC1st | — | — |
| 2017 | — | $4 MSEC2nd | $0 MSEC3rd | — | $0 MSEC3rd | $11 MSEC1st | — | — |
| 2016 | — | $1 MSEC2nd | — | — | $0 MSEC3rd | $12 MSEC1st | — | — |
| 2015 | — | $0 MSEC3rd | $0 MSEC4th | — | $0 MSEC2nd | $13 MSEC1st | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of ViewRay#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Nuwellis, Inc.NUWE · 🇺🇸 USASame industry: Medical Devices · Similar size: $3 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3 M (Oct 30, 2026) · revenue $8 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Guided Therapeutics Inc.GTHP · 🇺🇸 USASame industry: Medical Devices · Similar size: $7 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $7 M (last known, Jul 30, 2023) · revenue $1 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Nexalin Technology, Inc.NXL · 🇺🇸 USASame industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2 M (Oct 27, 2026) · revenue $0 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- ENvue Medical, Inc.FEED · 🇺🇸 USASame industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2 M (last known, Jan 5, 2024) · revenue $3 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Escalon Medical Corp.ESMC · 🇺🇸 USASame industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2 M (last known, Jul 30, 2023) · revenue $13 M (year to June 2026)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Nu-Med Plus Inc.NUMD · 🇺🇸 USASame industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2 M (last known, Jan 7, 2022)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- NeuroOne Medical Technologies CorporationNMTC · 🇺🇸 USASame industry: Medical Devices · Similar size: $8 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $8 M (Oct 30, 2026) · revenue $9 M (year to September 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Viveve MedicalVIVE · 🇺🇸 USASame industry: Medical Devices · Similar size: $4 M market cap against $4 M · Same country: USAMarket cap $4 M (last known, Dec 25, 2022)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
- Micron SolutionsMICR · 🇺🇸 USASame industry: Medical Devices · Similar size: $4 M market cap against $4 M · Same country: USAMarket cap $4 M (last known, Jul 30, 2023)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
- Aethlon Medical, Inc.AEMD · 🇺🇸 USASame industry: Medical Devices · Similar size: $9 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (Oct 30, 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Odyssey Group InternationalODYY · 🇺🇸 USASame industry: Medical Devices · Similar size: $9 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jul 30, 2023)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- ADM Tronics Unlimited Inc.ADMT · 🇺🇸 USASame industry: Medical Devices · Similar size: $10 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $10 M (last known, Jul 30, 2023) · revenue $3 M (year to March 2026)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.